)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gain Therapeutics
Gain Therapeutics (GANX) investor relations material
Gain Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Rexaceract is being developed for Parkinson’s disease with and without GBA1 mutations; Phase 2a is targeted to start in Q1 2027 after FDA IND authorization in June 2026.
Twelve-month open-label data showed stable MDS-UPDRS Parts II and III scores, generally good tolerability and no new safety signals.
Q3 losses narrowed as expenses declined, but $11.7M cash is expected to fund needs only into Q2 2027; additional financing is required.
Financial highlights
Q3 operating expenses were $3.20M versus $4.79M; R&D was $1.42M versus $2.85M, and G&A was $1.78M versus $1.94M.
Q3 net loss was $3.16M, or $0.07/share, versus $5.28M, or $0.15/share; nine-month net loss was $13.44M, or $0.31/share, versus $15.62M, or $0.50/share.
Nine-month R&D was $6.32M versus $7.87M; G&A was $6.91M versus $6.38M.
Cash and cash equivalents were $11.7M at September 30, 2026, versus $20.8M at December 31, 2025; accumulated deficit was $114.8M.
Nine-month operating cash use was $12.5M versus $13.8M; financing provided $3.5M versus $12.0M.
Outlook and guidance
Phase 1b Part 2 is expected to complete in Q4 2026; the Phase 2a protocol submission and design updates are expected in Q4 2026, with trial initiation targeted for Q1 2027.
Phase 2a is planned across U.S., Australian and European sites; timing depends on protocol redesign, regulatory submission and enrollment.
Cash is expected to fund anticipated operating and capital needs into Q2 2027, but not 12 months from financial-statement issuance; additional capital is required beyond Q2 2027.
R&D spending is expected to rise with clinical development; cost reviews and equity or debt financing, collaborations, licensing and grants are being pursued.
GT-04686’s initial target indication is expected in Q4 2026; a second allosteric small-molecule candidate is planned for clinical development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gain Therapeutics
- Rexaceract’s Phase 1b signals support a planned Q1 2027 Phase 2 Parkinson’s study.GANX
Corporate presentation - Rexaceract shows strong Phase 1b results for Parkinson's, with Phase 2 set for 2026.GANXCorporate presentation
- Phase 2 Parkinson's trial cleared as cash runway extends to Q2 2027, but funding risk persists.GANXQ2 2026
- GT-02287 shows promising disease-modifying potential in Parkinson's, advancing to phase II soon.GANX7th Annual HCW Neuro Perspectives Hybrid Conference
- GT-02287 demonstrated disease-modifying effects and is advancing to Phase 2 for Parkinson's.GANXCorporate presentation
- GT-02287 demonstrated strong disease-modifying potential in Parkinson's, with Phase 2 set for Q3 2026.GANXCorporate presentation
- Q1 2026 net loss reached $5.6M; cash runway extends into Q1 2027, with IND clearance expected.GANXQ1 2026
- Annual meeting to elect directors and ratify auditor, with strong governance and compensation oversight.GANXProxy filing
- GT-02287 reduced CSF glucosylsphingosine by 81% and improved UPDRS scores in Parkinson's patients.GANXStudy Update
Next Gain Therapeutics earnings date
Q4 202625 Mar, 2027
Gain Therapeutics
Next Gain Therapeutics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gain Therapeutics Inc. is a biotechnology firm engaged in the research and development of innovative therapies aimed at treating diseases caused by protein misfolding, with a focus on rare genetic diseases and neurological disorders. Utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform, the company identifies allosteric sites on misfolded proteins to discover proprietary small molecules that can bind to these sites, thereby restoring proper protein folding and addressing the underlying disease. Gain Therapeutics' lead product candidate is GT-02287, which targets GBA1 Parkinson's disease. Additionally, the company is advancing structurally targeted allosteric regulator candidates for a range of conditions, including Morquio B, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics is headquartered in Bethesda, Maryland, and its shares are listed on the NASDAQ under the ticker symbol GANX.